Preclinical News and Research

RSS

Prions and their shadow proteins: an interview with Dr Jiri Safar, Co-Director of the National Prion Disease Pathology Surveillance Center

The prion diseases were originally discovered by Dr Gajdusek and Dr Gibbs. The first disease discovered was Kuru, which was affecting native tribes in the Papua New Guinea highlands in the 1950s.

9 Feb 2014

Proprietary supplement improves cognitive processing speed of older adults

Declines in the underlying brain skills needed to think, remember and learn are normal in aging. In fact, this cognitive decline is a fact of life for most older Americans.

7 Feb 2014

Combination of etoposide with compounds that interfere with cell division improves therapeutic window for cancer treatments

A large part of the effort dedicated to cancer research is directed towards the search for combinations of existing drugs-many of which have already been introduced into clinical practice-that permit higher overall survival rates and improvements in the quality of life of cancer patients.

7 Feb 2014

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality.

6 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer's plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.

5 Feb 2014

Blood disorder medicines could be used for treating stomach and bowel cancer

Stomach and bowel cancer, two of the most common cancers worldwide, could be treated with a class of medicines that are currently used to treat a blood disorder, a Melbourne research team has discovered.

5 Feb 2014

Ablative Solutions completes $9.5M Series B Preferred Stock financing

Ablative Solutions, Inc., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has completed a Series B Preferred Stock financing, totaling approximately $9.5 million (including the conversion of the bridge financing completed in 2013), to fund its unique technology platform for renal denervation.

4 Feb 2014

Dormant prostate cancer cells in bone tissue can be reawakened, say researchers

Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute discovered in pre-clinical models that dormant prostate cancer cells found in bone tissue can be reawakened, causing metastasis to other parts of the body. Understanding this mechanism of action may allow researchers to intervene prior to disease progression.

31 Jan 2014

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.

31 Jan 2014

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.

31 Jan 2014

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.

30 Jan 2014

Researchers engineer skin cells for first time containing blood and lymphatic capillaries

Researchers at the University Children's Hospital Zurich and the University of Zurich have engineered skin cells for the very first time containing blood and lymphatic capillaries. They succeeded in isolating all the necessary types of skin cells from human skin tissue and engineering a skin graft that is similar to full-thickness skin.

30 Jan 2014

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins.

30 Jan 2014

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease.

30 Jan 2014

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine).

30 Jan 2014

AMSilk completes preclinical testing of proprietary silicone breast implant coating

AMSilk has completed preclinical testing of its proprietary silicone implant coating made from spider silk. AMSilk's coating consists of a thin layer of spider silk proteins manufactured by AMSilk.

29 Jan 2014

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years.

28 Jan 2014

Researchers develop valid humanized model for facioscapulohumeral muscular dystrophy

Researchers at the Kennedy Krieger Institute recently announced study findings showing the successful development of a humanized preclinical model for facioscapulohumeral muscular dystrophy (FSHD), providing scientists with a much needed tool to accelerate novel therapeutic research and development.

28 Jan 2014

Preclinical News and Research

Prions and their shadow proteins: an interview with Dr Jiri Safar, Co-Director of the National Prion Disease Pathology Surveillance Center

Proprietary supplement improves cognitive processing speed of older adults

Combination of etoposide with compounds that interfere with cell division improves therapeutic window for cancer treatments

TSRI scientists design artificial proteins as a candidate vaccine against RSV

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Fraunhofer USA receives FDA clearance for IND malaria TBV that targets Pfs25 antigen

Blood disorder medicines could be used for treating stomach and bowel cancer

Ablative Solutions completes $9.5M Series B Preferred Stock financing

Dormant prostate cancer cells in bone tissue can be reawakened, say researchers

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Researchers engineer skin cells for first time containing blood and lymphatic capillaries

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

TCGA Research Network identify new potential therapeutic targets for major form of bladder cancer

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

AMSilk completes preclinical testing of proprietary silicone breast implant coating

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Researchers develop valid humanized model for facioscapulohumeral muscular dystrophy

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics